Crossmark

CXCL9 and IL-18: potential biomarkers for efficacy evaluation in refractory hemophagocytic lymphohistiocytosis treated with RED (ruxolitinib, emapalumab and dexamethasone)

Crossref DOI link: https://doi.org/10.1007/s00277-025-06336-8

Published Online: 2025-04-05

Published Print: 2025-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lan, Xuan

Wei, Na

Wang, Jingshi

Wang, Zhao
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (82370185)
License Information

Text and Data Mining valid from 2025-03-01

Version of Record valid from 2025-04-05
More Information

Article History

Received: 29 July 2024

Accepted: 23 March 2025

First Online: 5 April 2025

Declarations

:

: This study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Beijing Friendship hospital (Approval No. 2023-P2-321, Date: 2023-11-30).

: All human participants involved in this study provided their informed consent prior to participation. The study was conducted in accordance with ethical guidelines, and participants were informed about the purpose, procedures, potential risks, and their right to withdraw at any time without consequences. Written (or verbal, if applicable) consent was obtained from all individuals before their inclusion in the study.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below